Selecta hires Lonza to make synthetic vector delivered gene therapy
Selecta Biosciences Inc. has hired Swiss contractor Lonza to make a gene therapy candidate for the metabolic disease, Methylmalonic Acidemia (MMA).
Archives for February 17, 2017
Strategic CRO takes $100m hit from Pfizer's shelved PCSK9 candidate
Contract research organisation (CRO) ICON has taken a hit to its book-to-bill ratio after Pfizer dropped its anti-cholesterol candidate bococizumab in November.